Studies published in “Blood” demonstrate that MUC1-C drives MYC expression in multiple myeloma. These findings are of importance in that GO-203 treatment represents a novel therapeutic approach to target MYC in multiple myeloma cells that are addicted to MYC for their growth and survival.
RSS Feed
